Cardiovascular Dysfunction in Intrauterine Growth Restriction.

IF 3.9 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Hypertension Reports Pub Date : 2022-12-01 Epub Date: 2022-11-02 DOI:10.1007/s11906-022-01228-y

Narayanappa Amruta, Hemanth Kumar Kandikattu, Suttira Intapad

{"title":"Cardiovascular Dysfunction in Intrauterine Growth Restriction.","authors":"Narayanappa Amruta, Hemanth Kumar Kandikattu, Suttira Intapad","doi":"10.1007/s11906-022-01228-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: We highlight important new findings on cardiovascular dysfunction in intrauterine growth restriction.Recent findings: Intrauterine growth restriction (IUGR) is a multifactorial condition which negatively impacts neonatal growth during pregnancy and is associated with health problems during the lifespan. It affects 5-15% of all pregnancies in the USA and Europe with varying percentages in developing countries. Epidemiological studies have reported that IUGR is associated with the pathogenesis of hypertension, activation of the renin-angiotensin system (RAS), disruption in placental-mTORC and TGFβ signaling cascades, and endothelial dysfunction in IUGR fetuses, children, adolescents, and adults resulting in the development of cardiovascular diseases (CVD). Experimental studies are needed to investigate therapeutic measures to treat increased blood pressure (BP) and long-term CVD problems in people affected by IUGR. We outline the mechanisms mediating fetal programming of hypertension in developing CVD. We have reviewed findings from different experimental models focusing on recent studies that demonstrate CVD in IUGR.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"24 12","pages":"693-708"},"PeriodicalIF":3.9000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-022-01228-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: We highlight important new findings on cardiovascular dysfunction in intrauterine growth restriction.

Recent findings: Intrauterine growth restriction (IUGR) is a multifactorial condition which negatively impacts neonatal growth during pregnancy and is associated with health problems during the lifespan. It affects 5-15% of all pregnancies in the USA and Europe with varying percentages in developing countries. Epidemiological studies have reported that IUGR is associated with the pathogenesis of hypertension, activation of the renin-angiotensin system (RAS), disruption in placental-mTORC and TGFβ signaling cascades, and endothelial dysfunction in IUGR fetuses, children, adolescents, and adults resulting in the development of cardiovascular diseases (CVD). Experimental studies are needed to investigate therapeutic measures to treat increased blood pressure (BP) and long-term CVD problems in people affected by IUGR. We outline the mechanisms mediating fetal programming of hypertension in developing CVD. We have reviewed findings from different experimental models focusing on recent studies that demonstrate CVD in IUGR.

Abstract Image

查看原文本刊更多论文

宫内生长受限的心血管功能障碍

综述的目的：我们重点介绍有关宫内生长受限导致心血管功能障碍的重要新发现：宫内生长受限（IUGR）是一种多因素疾病，会对孕期新生儿的生长产生负面影响，并与一生中的健康问题有关。在美国和欧洲，5%-15% 的孕妇会受到这种疾病的影响，发展中国家的比例也不尽相同。流行病学研究表明，IUGR 与高血压的发病机制、肾素-血管紧张素系统（RAS）的激活、胎盘-mTORC 和 TGFβ 信号级联的破坏以及 IUGR 胎儿、儿童、青少年和成人的内皮功能障碍有关，从而导致心血管疾病（CVD）的发生。我们需要开展实验研究，探讨治疗措施，以治疗 IUGR 患者的血压（BP）升高和长期心血管疾病问题。我们概述了高血压在心血管疾病发展过程中的胎儿编程机制。我们回顾了不同实验模型的研究结果，重点是最近证明 IUGR 会导致心血管疾病的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hypertension Reports 医学-外周血管病

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.